HIGHLIGHTS
- who: Su00e9bastien Reig from the France National Autonomous University of have published the paper: What Is New in the Antiu2013Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert?, in the Journal: (JOURNAL) of December/16,/2019
- what: This study had several limitations and encountered many unexpected difficulties.
- future: Post hoc subgroup analyses support mechanism of action for OligoG and warrant further prospective studies (Van Koningsbruggen-Rietschel et_al 2020).
SUMMARY
Although formal data are lacking, the vaccine, by limiting the use of antibiotics and thus reducing selection pressure on . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.